Recruiting

N/A

36

 

BCMA-CAR-T cells (ICG186)2.5 x10*5/kg ;BCMA-CAR-T cells (ICG186)5 x10*5/kg ;BCMA-CAR-T cell (ICG186)10 x10*5/kg ;BCMA-CAR-T cells (ICG186)20 x10*5/kg ;BCMA/CS1-CAR-T cells (ICG180)2.5 x10*5/kg ;BCMA/CS1-CAR-T cells (ICG180)5 x10*5/kg ;BCMA/CS1-CAR-T cells (ICG180)10x10*5/kg ;BCMA/CS1-CAR-T cells (ICG180)20x10*5/kg ;BCMA/CD19-CAR-T cells (ICG181)2.5x10*5/kg ;BCMA/CD19-CAR-T cells (ICG181)5x10*5/kg ;BCMA/CD19-CAR-T cells (ICG181)10x10*5/kg ;BCMA/CD19-CAR-T cells (ICG181)10x10*5/kg

Department of Hematology, The First Affiliated Hospital of Xiamen University; Level of the institution：, Guiqidan Biomedicine(Zhongshan) Co. Ltd.

Relapsed/refractory Malignant plasmacyte disease